MedTrace Logo

Project Motion, A Study of Motivational Interviewing to Reduce Heavy or Problematic Drinking

NCT00665249 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2015-04-28

No results posted yet for this study

Summary

The purpose of this pilot study is to investigate the critical components of motivational interviewing (MI), a psychotherapeutic intervention, in reducing heavy or problematic drinking. The study will disaggregate MI into its component parts and test full MI compared to MI without its directive strategies. This study will test whether the directive elements of MI are critical or whether MI effects may be attributable solely to its Rogerian, non-directive components. For more information, go to www.projectmotion.org

Conditions

  • Alcohol Dependence
  • Alcohol Abuse

Interventions

BEHAVIORAL

Motivational Interviewing

See MotivationalInterviewing.org

BEHAVIORAL

Spirit-Only Motivational Interviewing

Non-directive elements encompass the use of MI-consistent, and avoidance of MI-inconsistent, behaviors, as well as attention to MI-spirit.

OTHER

Self-Change

Participants are followed for 8 weeks, without therapeutic intervention. At end of assessment period, they receive 4 sessions of full MI.

Sponsors & Collaborators

  • Northwell Health

    lead OTHER

Principal Investigators

  • Jon Morgenstern, Ph.D. · Columbia University

  • Alexis N Kuerbis, MSW, PhD · Research Foundation for Mental Hygiene, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2009-05-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00665249 on ClinicalTrials.gov